Credit Suisse’s Lifecore Biomedical LFCR Stock Holding History

Credit Suisse’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$6	–	3531
2022 Q4	$6	Sell	1 -147	-99%	-$1.21K	﹤0.01%	3798
2022 Q3	$1K	Buy	148 +121	+448%	+$1.23K	﹤0.01%	3873
2022 Q2	$0	Buy	+27	New	+$267	﹤0.01%	4141
2021 Q4	–	Sell	-17,667	Closed	-$162K	–	4605
2021 Q3	$162K	Buy	17,667 +2,550	+17%	+$27.7K	﹤0.01%	4266
2021 Q2	$170K	Buy	15,117 +197	+1%	+$2.27K	﹤0.01%	4307
2021 Q1	$158K	Sell	14,920 -12,282	-45%	-$138K	﹤0.01%	4157
2020 Q4	$295K	Buy	27,202 +14,476	+114%	+$150K	﹤0.01%	3993
2020 Q3	$124K	Sell	12,726 -1,785	-12%	-$17K	﹤0.01%	3904
2020 Q2	$116K	Buy	14,511 +3,405	+31%	+$35.1K	﹤0.01%	3824
2020 Q1	$96K	Sell	11,106 -2,434	-18%	-$25.3K	﹤0.01%	3830
2019 Q4	$153K	Sell	13,540 -2,804	-17%	-$29.8K	﹤0.01%	4031
2019 Q3	$177K	Sell	16,344 -2,171	-12%	-$23.6K	﹤0.01%	3888
2019 Q2	$173K	Buy	18,515 +873	+5%	+$8.81K	﹤0.01%	3875
2019 Q1	$217K	Sell	17,642 -14,017	-44%	-$171K	﹤0.01%	3737
2018 Q4	$376K	Buy	31,659 +2,638	+9%	+$36.2K	﹤0.01%	3406
2018 Q3	$418K	Sell	29,021 -7,693	-21%	-$106K	﹤0.01%	3393
2018 Q2	$547K	Sell	36,714 -3,368	-8%	-$46.8K	﹤0.01%	3375
2018 Q1	$522K	Buy	40,082 +2,152	+6%	+$28.3K	﹤0.01%	3339
2017 Q4	$478K	Sell	37,930 -12,757	-25%	-$161K	﹤0.01%	3456
2017 Q3	$656K	Buy	50,687 +13,628	+37%	+$180K	﹤0.01%	3388
2017 Q2	$550K	Sell	37,059 -423	-1%	-$5.89K	﹤0.01%	3089
2017 Q1	$449K	Buy	37,482 +3,747	+11%	+$47.4K	﹤0.01%	3358
2016 Q4	$465K	Buy	33,735 +2,113	+7%	+$29.3K	﹤0.01%	3491
2016 Q3	$424K	Sell	31,622 -6,337	-17%	-$76.8K	﹤0.01%	3507
2016 Q2	$409K	Sell	37,959 -4,130	-10%	-$45.6K	﹤0.01%	3537
2016 Q1	$442K	Sell	42,089 -8,087	-16%	-$88.8K	﹤0.01%	3318
2015 Q4	$594K	Sell	50,176 -728	-1%	-$8.94K	﹤0.01%	3237
2015 Q3	$594K	Buy	50,904 +18,057	+55%	+$239K	﹤0.01%	3275
2015 Q2	$474K	Buy	32,847 +4,503	+16%	+$65K	﹤0.01%	3764
2015 Q1	$395K	Sell	28,344 -10,954	-28%	-$151K	﹤0.01%	3698
2014 Q4	$543K	Buy	39,298 +2,497	+7%	+$32.3K	﹤0.01%	3650
2014 Q3	$451K	Buy	36,801 +7,106	+24%	+$88.7K	﹤0.01%	3711
2014 Q2	$371K	Sell	29,695 -22,097	-43%	-$260K	﹤0.01%	3986
2014 Q1	$578K	Sell	51,792 -241,373	-82%	-$2.65M	﹤0.01%	3599
2013 Q4	$3.55M	Sell	293,165 -34,487	-11%	-$412K	﹤0.01%	2134
2013 Q3	$4M	Buy	327,652 +33,394	+11%	+$466K	﹤0.01%	1826
2013 Q2	$3.89M	Buy	+294,258	New	+$4.07M	﹤0.01%	1785

Other funds holding LFCR

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

Credit Suisse's LFCR Position: Q1 2023 in Review

Credit Suisse sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 1 share — an estimated $6 sold.

Credit Suisse first reported a position in LFCR in Q2 2013 and held it in 37 quarters. The position peaked at $4M in Q3 2013. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

Credit Suisse reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
Credit Suisse sold 1 Lifecore Biomedical share in Q1 2023, an estimated $6.
Credit Suisse first reported a position in Lifecore Biomedical in Q2 2013 and held it in 37 quarters.
Credit Suisse's Lifecore Biomedical position peaked at $4M in Q3 2013.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.